Using CB-839 to Inhibit GLS
Mechanism and Concentration
CB-839 (telaglenastat) is a non-competitive, selective inhibitor of GLS1, with much lower potency against GLS2.
| Concentration | Context | Note |
|---|---|---|
| 0.1–0.5 µM | Cellular IC50 range in sensitive lines | Requires sensitive readout |
| 1 µM | The most commonly used concentration | Adequate in many lines |
| 2–5 µM | Higher end; used in resistant lines | Off-target risk rises |
| Above 10 µM | Rarely justified | Not a GLS-specific experiment |
Caveat on potency variation. Cellular potency depends on glutamine concentration, because the inhibition is non-competitive with respect to glutamine but the pathway flux depends on substrate supply. In medium with 4 mM glutamine, a higher CB-839 concentration is needed to suppress flux than in medium with 1 mM. The concentration and the medium belong together.
Part 1 — Design
| Parameter | Recommendation | Why |
|---|---|---|
| Pre-incubation | 1–4 h before the assay | Slower effect than a direct enzyme inhibitor |
| Glutamine concentration | State it; test at least two | Determines the apparent potency |
| On-target control | GLS1 knockdown, or GLS2-expressing comparator | Specificity |
| Rescue | Cell-permeable α-KG (dimethyl-α-KG), nucleosides, NAC | Which role mattered |
| Readouts | Glutamate release, ¹³C-glutamine into TCA, growth | Flux plus phenotype |
| Viability timepoint | Early and late | Separates metabolic from cytotoxic effects |
The second row is the one that most often changes the result. A GLS dependency in 0.5 mM glutamine can disappear at 4 mM, because glutamate import and alternative anaplerosis become sufficient. Reporting one concentration without the other gives a result that does not generalise.
Part 2 — The α-Ketoglutarate Rescue and Its Problems
The logic is appealing: if GLS inhibition works by starving the TCA cycle of α-KG, then supplying α-KG should rescue. The execution is less clean.
| Issue | Detail |
|---|---|
| Permeability | α-KG itself is poorly cell-permeable; the dimethyl ester is used |
| Concentration | Millimolar concentrations are required, with osmotic and pH effects |
| Metabolism | Supplied α-KG is metabolised, not inert; it can be oxidised or transaminated |
| Ammonia | Some α-KG preparations carry ammonium; check |
| Specificity | α-KG can affect signalling (prolyl hydroxylases; epigenetic enzymes) |
Readout note. A rescue with 4 mM dimethyl-α-KG that restores growth is consistent with anaplerotic rescue, but the concentration is high enough that osmotic and pH controls are required. A rescue at 1 mM that is partial is more interpretable and is worth trying first.
Part 3 — What the Inhibitor Does Not Tell You
- • That GLS was the only affected step. Glutamate can be imported and can come from protein turnover.
- • That anaplerosis was the relevant function. Nitrogen donation, glutathione synthesis and nucleotide synthesis are all GLS-dependent.
- • That the effect is tumour-selective. Sensitivity varies with glutamine supply, GLS2 expression and alternative anaplerosis.
- • That a growth effect is a viability effect. Growth arrest and death are different endpoints.
Part 4 — Model Requirements and Recurring Failures
| Requirement | Why |
|---|---|
| Medium glutamine stated | Sets potency and dependency |
| Medium age recorded | Glutamine degrades; ammonia accumulates |
| GLS1 and GLS2 status | Determines inhibitor effect |
| Glutamate import considered | Can bypass the enzyme |
| Ammonia measured | Product of the inhibited pathway |
| Viability and growth both measured | Different endpoints |
Recurring failures:
- • Single concentration, single medium, with the dependency generalised.
- • No on-target control, so an off-target effect is indistinguishable.
- • α-KG rescue without osmotic control.
- • Growth reported as viability.
- • Glutamate release not measured, so target engagement is unconfirmed.
- • Medium age unrecorded, so glutamine depletion is attributed to the drug.
Part 5 — Interpreting a Negative Result
A line that does not respond to CB-839 is informative.
| Explanation | Test |
|---|---|
| Glutamate import sufficient | Glutamine-free and glutamate-free medium |
| Alternative anaplerosis (pyruvate carboxylase) | Knockdown of PC or of the alternative route |
| Low GLS1 expression | Measure GLS1; check GLS2 |
| High glutamine medium | Repeat at 0.5–1 mM |
| Salvage of nitrogen from other sources | Single amino acid dropout panel |
A negative result with these controls is a statement about the model's metabolic wiring, which is a useful result and is rarely reported as one.
If you need GLS dependency tested across glutamine concentrations with rescue and on-target controls, we can scope the design with you.
Contact EDITGENE to request a project consultation or quote.
Scientific scope and validation note
Potency, sensitivity and rescue requirements vary with cell type, glutamine concentration and alternative substrate availability. The concentrations here are starting points.
Inhibition of GLS does not establish which glutamine function was required, and growth arrest does not establish cell death.
Scientific interpretation and experimental design
- • Potency depends on glutamine. Report both.
- • Pre-incubate. The effect is not instantaneous.
- • On-target control is mandatory. Knockdown, or GLS2 comparison.
- • α-KG rescue has its own effects. Control osmolarity and pH.
- • Glutamate release confirms engagement.
- • A negative result can be the finding.
Selected references for further reading
- • Gross MI, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Molecular Cancer Therapeutics. 2014;13:890–901.
- • Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nature Reviews Cancer. 2016;16:619–634.
- • Biancur DE, et al. Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism. Nature Communications. 2017;8:15965.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »